Skip to main content
Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
Drug guidance

Bevacizumab for treating persistent, recurrent or metastatic cervical cancer

Cancer

Gynaecological

12 July 2022

Guidance Recommendations

Back to top